Axsome Therapeutics, Inc. (AXSM)
AXSM moved a median of +0.05% 30 minutes after news, and +0.08% by the close. How AXSM actually reacts to news — the realized, point-in-time move the market made, measured across 391 labeled events over the last three years with zero look-ahead.
AXSM’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.02% | 51% | 390 |
| 30-min | +0.05% | 52% | 390 |
| 60-min | +0.29% | 57% | 391 |
| to close | +0.08% | 55% | 388 |
| Middle 50% of AXSM reactions | -0.82% to +0.93% |
|---|---|
| Median reaction (30-min) | +0.05% |
| Measured reactions | 391 |
Half of all Axsome Therapeutics, Inc. news events land between -0.82% and +0.93% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How AXSM reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 18 | +0.24% | 56% | +0.97% |
| Coverage initiations | 42 | -0.14% | 38% | +0.41% |
| Rating reiterations | 222 | -0.00% | 49% | -0.12% |
| Price-target raises | 41 | -0.17% | 37% | +0.14% |
| Price-target cuts | 13 | +0.09% | 54% | -0.19% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 1 further class was observed with fewer than 10 measured events and is not published. See how AXSM ranks against every other measured name →
That’s how AXSM usually reacts — get an email when it moves on news →Email me when AXSM moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to AXSM's baseline. Nothing else.
Recent AXSM events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Axsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2 | Press release | GlobeNewswire | -0.31% | -0.59% | |
| Axsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer’s Disease Agitation Presented at Psych Congress 2026 in Connection with World Alzheimer’s Day | Press release | GlobeNewswire | -0.21% | -1.29% | |
| Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026 | Press release | GlobeNewswire | +0.37% | -0.61% | |
| Axsome Therapeutics to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +1.20% | +3.35% | |
| Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation | Press release | GlobeNewswire | -0.25% | -0.24% | |
| Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | -0.23% | — | |
| Form 8-K Axsome Therapeutics, For: Aug 10 | SEC filing · Form 8-K | SEC EDGAR | -0.23% | — | |
| Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy | Press release | GlobeNewswire | -0.80% | +2.13% | |
| Form 8-K Axsome Therapeutics, For: Jul 15 | SEC filing · Form 8-K | SEC EDGAR | -0.80% | +2.13% | |
| Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10 | Press release | GlobeNewswire | -0.19% | +2.73% | |
| Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD) | Press release | GlobeNewswire | -0.93% | +3.08% | |
| Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD) | Press release | GlobeNewswire | -0.30% | +0.75% | |
| Axsome Therapeutics Highlights the Importance of Brain Health During Alzheimer's & Brain Awareness Month | Press release | GlobeNewswire | -0.86% | -1.38% | |
| Axsome Therapeutics Presents New Data Highlighting its Innovative Sleep Medicine Portfolio at SLEEP 2026 | Press release | GlobeNewswire | -0.36% | -0.01% | |
| Form 8-K Axsome Therapeutics, For: Jun 05 | SEC filing · Form 8-K | SEC EDGAR | +1.15% | +0.07% | |
| Axsome Therapeutics Presents New SYMBRAVO® Data at the Americal Headache Society (AHS) 68th Annual Scientific Meeting | Press release | GlobeNewswire | -1.00% | -0.99% | |
| Axsome Therapeutics Announces Settlement Resolving All SUNOSI® (solriamfetol) Patent Litigation | Press release | GlobeNewswire | -2.00% | +3.68% | |
| Form 8-K Axsome Therapeutics, For: Jun 03 | SEC filing · Form 8-K | SEC EDGAR | -2.00% | +3.68% | |
| Axsome Therapeutics Partners with the Headache Alliance to Highlight the Impact of Migraine During Migraine and Headache Awareness Month | Press release | GlobeNewswire | -0.98% | -1.39% | |
| Axsome Therapeutics to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | -0.73% | -0.20% | |
| Axsome Therapeutics Presents New AUVELITY® Data in Major Depressive Disorder at the American Society of Clinical Psychopharmacology (ASCP) 2026 Annual Meeting | Press release | GlobeNewswire | -0.72% | -1.09% | |
| Axsome Therapeutics Recognizes Mental Health Month | Press release | GlobeNewswire | -0.38% | -0.06% | |
| Axsome Therapeutics to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +1.33% | -0.86% | |
| Axsome Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | +5.90% | +7.29% | |
| Form 10-Q Axsome Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.33% | -0.86% | |
| Form 8-K Axsome Therapeutics, For: May 04 | SEC filing · Form 8-K | SEC EDGAR | +5.90% | +7.29% | |
| Axsome Therapeutics Hosts AUVELITY® FDA Approval Investor Event Featuring Expert Thought Leader | Press release | GlobeNewswire | -1.34% | -0.59% | |
| Axsome Therapeutics Announces FDA Approval of AUVELITY® (dextromethorphan HBr and bupropion HCl) for the Treatment of Agitation Associated with Dementia due to Alzheimer’s Disease | Press release | GlobeNewswire | — | +11.37% | |
| Form 8-K Axsome Therapeutics, For: Apr 30 | SEC filing · Form 8-K | SEC EDGAR | -1.34% | -0.59% | |
| Form ARS Axsome Therapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +1.42% | +0.48% | |
| Form DEF 14A Axsome Therapeutics, For: Apr 24 | SEC filing · Form DEF | SEC EDGAR | +1.42% | +0.48% | |
| Form DEFA14A Axsome Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | +1.42% | +0.48% | |
| Axsome Therapeutics to Report First Quarter 2026 Financial Results on May 4 | Press release | GlobeNewswire | -1.65% | +0.69% | |
| Axsome Therapeutics Acquires Selective PDE10A Inhibitor Balipodect for the Treatment of Schizophrenia and Other Neuropsychiatric Conditions | Press release | GlobeNewswire | +1.77% | +0.76% | |
| Form 8-K Axsome Therapeutics, For: Apr 01 | SEC filing · Form 8-K | SEC EDGAR | +1.77% | +0.76% | |
| Axsome Therapeutics to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | -2.38% | -3.82% | |
| Axsome Therapeutics Initiates CLARITY Phase 3 Trial of Solriamfetol in Adults with Major Depressive Disorder with Excessive Daytime Sleepiness Symptoms | Press release | GlobeNewswire | -2.55% | -2.74% | |
| Axsome Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | +2.31% | +0.59% | |
| Form 10-K Axsome Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -2.55% | -2.74% | |
| Form 8-K Axsome Therapeutics, For: Feb 23 | SEC filing · Form 8-K | SEC EDGAR | +2.31% | +0.59% | |
| Axsome Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference | Press release | GlobeNewswire | +0.64% | +1.17% | |
| Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Alkem Laboratories Ltd. | Press release | GlobeNewswire | -1.15% | -0.19% | |
| Form 8-K Axsome Therapeutics, For: Feb 17 | SEC filing · Form 8-K | SEC EDGAR | -1.15% | -0.19% | |
| Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23 | Press release | GlobeNewswire | +0.99% | +1.40% | |
| Axsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for the Management of Fibromyalgia | Press release | GlobeNewswire | -0.73% | -1.62% | |
| Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue | Press release | GlobeNewswire | -0.00% | +2.50% | |
| Form 8-K Axsome Therapeutics, For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | -0.00% | +2.50% | |
| Axsome Therapeutics Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for AXS-05 for the Treatment of Alzheimer’s Disease Agitation | Press release | GlobeNewswire | +3.91% | +15.24% | |
| Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-12 in Narcolepsy Supporting NDA Submission | Press release | GlobeNewswire | +3.91% | +15.24% | |
| Form 8-K Axsome Therapeutics, For: Dec 31 | SEC filing · Form 8-K | SEC EDGAR | +3.91% | +15.24% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the AXSM section they belong to.
Where else AXSM is measured.
AXSM earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Rubius Therapeutics, Inc. (RUBY) | 392 | -0.32% | 45% |
| Arrowhead Pharmaceuticals, Inc. (ARWR) | 391 | +0.13% | 52% |
| RA PHARMACEUTICALS (RARX) | 391 | -0.04% | 45% |
| Checkpoint Therapeutics, Inc. (CKPT) | 389 | 0.00% | 49% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Axsome Therapeutics, Inc.'s median reaction calculated?
Every labeled AXSM news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 391 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 52% of AXSM's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does AXSM's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.